Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is... Dirucotide has been developed for the treatment of multiple sclerosis (MS).
- Mechanism
- Curator reviewed
The apparent mechanism of action of MBP8298 is the induction or restoration of immunological tolerance with respect to ongoing immune attack at this molecular site. High doses of antigen delivered periodically by the intravenous route are expected to suppress immune responses to the administered substance. The potential benefit of MBP8298 for any individual patient is therefore expected to be related to the extent to which his or her disease process is dominated by autoimmune attack at the site represented by this synthetic peptide.
- Primary indication
- For the treatment of multiple sclerosis (MS).Curator reviewed
- Code names
- MBP8298
Resolves to
What you can answer from here — as of February 21, 2021
Which companies are running trials of Dirucotide, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account